Exendin-4 analogs in insulinoma theranostics.

Autor: Jansen TJP; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands., van Lith SAM; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands., Boss M; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands., Brom M; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands., Joosten L; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands., Béhé M; Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute, Villigen, Switzerland., Buitinga M; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.; Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium., Gotthardt M; Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
Jazyk: angličtina
Zdroj: Journal of labelled compounds & radiopharmaceuticals [J Labelled Comp Radiopharm] 2019 Aug; Vol. 62 (10), pp. 656-672.
DOI: 10.1002/jlcr.3750
Abstrakt: Insulinomas, neuroendocrine tumors arising from pancreatic beta cells, often show overexpression of the glucagon-like peptide-1 receptor. Therefore, imaging with glucagon-like peptide analog exendin-4 can be used for diagnosis and preoperative localization. This review presents an overview of the development and clinical implementation of exendin-based tracers for nuclear imaging, and the potential use of exendin-4 based tracers for optical imaging and therapeutic applications such as peptide receptor radionuclide therapy or targeted photodynamic therapy.
(© 2019 The Authors Journal of Labelled Compounds and Radiopharmaceuticals Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje